IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.
The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.
IN8BIO director Greenwood Luba received a stock option grant for 22,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. One-twelfth of the shares vest monthly starting June 9, 2026, with full vesting at the next annual stockholders’ meeting if service continues.
IN8BIO, INC. executive Lawrence Lamb, EVP and CSO, received an employee stock option grant covering 54,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. After this grant, Lamb holds options for 54,000 shares directly.
According to the vesting terms, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to Lamb continuing to provide service through each vesting date.
IN8BIO, INC. director Emily Fairbairn received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in 12 equal monthly installments starting on June 9, 2026 and will in any case be fully vested on the date of the company’s next annual meeting of stockholders, subject to her continued service. These options expire on May 9, 2036, and following this grant she holds 22,000 stock options directly.
IN8bio, Inc. reported that its Chief Financial Officer, Patrick McCall, received an employee stock option grant for 56,250 options to buy common stock at an exercise price of $1.58 per share. Following this grant, he holds 56,250 derivative securities directly.
The option vests in four equal parts, with 25% of the shares vesting on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as he continues providing service through each vesting date. The option expires on May 9, 2036.
IN8BIO, INC. director Corinne Epperly received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036, and represent a compensation-related award rather than an open-market trade.
One twelfth of the options vest in equal monthly installments starting on June 9, 2026, with full vesting no later than the company’s next annual meeting of stockholders, as long as she continues providing service through each vesting date.
IN8BIO, INC. reported that President and COO Kate Rochlin received a grant of employee stock options covering 60,000 shares of common stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036.
These compensation-related options were awarded with no cash paid by the executive at grant. According to the vesting schedule, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as she continues providing service through each date. After this grant, she holds options for 60,000 underlying shares directly.
IN8BIO, INC. director Peter C. Brandt received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in equal monthly installments over 12 months starting on June 9, 2026, and any unvested portion becomes fully vested on the date of the company’s next annual stockholder meeting, subject to continued service. Following this grant, Brandt holds 22,000 stock options directly.
IN8BIO, INC. director Jeremy R. Graff received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $1.5800 per share and expire on May 9, 2036. One-twelfth of the options vest monthly starting June 9, 2026, or they become fully vested on the date of the company’s next annual stockholder meeting if he continues providing service.
IN8bio, Inc. reports Q1 2026 results and highlights substantial doubt about its ability to continue as a going concern. The clinical-stage biotech posted a net loss of $5.1 million, slightly improved from $5.6 million a year earlier, as operating expenses fell to $5.3 million.
Cash was $21.9 million as of March 31, 2026, which management expects to fund operations only into April 2027. With an accumulated deficit of $146.2 million and no product revenue, the company plans to prioritize its pipeline, seek additional equity or debt financing, and pursue collaborations.
IN8bio’s programs include INB-100 for high-risk leukemias, INB-200/400 for glioblastoma, and INB-619, a CD19-targeted T cell engager for autoimmune diseases, though several preclinical efforts remain paused to conserve cash.